CTI Molecular Imaging Announces Resignation of Member of Senior Management

CTI Molecular Imaging Announces Resignation of Member of Senior
Management 


KNOXVILLE, Tenn., Aug. 31  /PRNewswire-FirstCall/ -- CTI Molecular Imaging,
Inc. (NASDAQ:CTMI), a leading provider of positron emission tomography (PET)
equipment, molecular biomarkers and services, today announced the resignation
of Thomas J. Hook, who most recently has served as Senior Vice President of CTI
Molecular Imaging and President of CTI Solutions.  Mr. Hook has resigned from
CTI in order to accept a position with another company.

"On behalf of all of us at CTI Molecular Imaging, I want to thank Tom for his
many contributions to our organization.  Under Tom's leadership, we established
a strong presence in the distribution of scanners, as well as experienced a
rapid growth in our PETNET operations.  Through his focus on improving our
sales capabilities, Tom has grown our market share and profitability in these
key areas.  Tom is a talented manager and a fine individual, and we wish him
the very best in his new pursuits," said Ronald Nutt, Ph.D., President and
Chief Executive Officer of CTI Molecular Imaging.

CTI has not announced any promotions or replacements for the position. Mr.
Hook's resignation is effective September 1, 2004.

About CTI Molecular Imaging:

CTI Molecular Imaging, Inc. is a leading supplier of products and services for
positron emission tomography (PET), a diagnostic imaging technology used in the
detection and treatment of cancer, neurological disorders, and cardiac disease.
 Additional information is available at: http://www.ctimi.com/ .

Certain matters discussed in this press release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995.  Such forward-looking statements, which may be identified by words
such as "assume," "expect," "anticipate," "intend," "estimate" or similar
expressions, include statements regarding the anticipated financial impact and
operational improvements resulting from the new distribution arrangement with
Siemens and any other statements that necessarily depend on future events.
Forward-looking statements involve a number of risks and uncertainties and
there can be no assurance that any forward-looking statements will prove to be
accurate.  Various factors could cause actual results to differ materially from
those anticipated in the forward-looking statements.  CTI undertakes no
obligation to update or revise any forward-looking statements. Further
information regarding risks, uncertainties and other factors that could
adversely affect CTI or cause actual results to differ materially from those
anticipated in forward-looking statements are included in CTI's Annual Report
on Form 10-K for the fiscal year ended September 30, 2003 and Quarterly Report
on Form 10-Q for the quarter ended June 30, 2004. 

DATASOURCE: CTI Molecular Imaging, Inc.



CONTACT:  Michael A. Lawless of CTI Molecular Imaging, Inc.,

[phone]



Web site:  http://www.ctimi.com/ 

Copyright